$1.00 per share is the Nasdaq minimum bid price Invivyd, Inc. (IVVD) failed to clear for 30 consecutive business days, drawing a deficiency letter from the Nasdaq Listing Qualifications Department dated July 23, 2026. Under Nasdaq Listing Rule 5810(c)(3)(A), the New Haven, Connecticut biotech has until January 19, 2027 to restore its closing bid above that floor or face removal from The Nasdaq Global Market. The letter itself carries no immediate effect; IVVD continues to trade on Nasdaq under its existing ticker.
The compliance clock
The Initial Compliance Period runs from the letter date to January 19, 2027. To cure the deficiency within that window, Invivyd must record a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq Listing Rule 5450(a)(1) sets the $1.00 floor; Listing Rule 5810(c)(3)(H) grants staff discretion to extend that ten-day cure window.
The 8-K states Invivyd will actively monitor its closing bid price and consider available options to resolve the deficiency. The filing names no specific remedy, reverse split, or capital action.
Second compliance period and delisting mechanics
A second path exists if January 19, 2027 passes without a cure. The Second Compliance Period adds 180 calendar days but attaches conditions: Invivyd must transfer from The Nasdaq Global Market to The Nasdaq Capital Market, meet Capital Market continued listing requirements for market value of publicly held shares, and formally notify Nasdaq of its intent to cure. Nasdaq staff then independently determines whether a cure is achievable before granting the extension.
Staff rejection at any stage, or failure to comply within the allotted period, triggers written notice of delisting. Invivyd could appeal that determination to a Nasdaq Hearings Panel. The filing, signed by Chief Legal Officer and Corporate Secretary Jill Andersen on July 24, 2026, offers no assurance that any such appeal would succeed.
Company and filing data
Invivyd, Inc. is incorporated in Delaware with principal offices at 209 Church Street, New Haven, CT 06510. The company holds Commission File Number 001-40703, carries common stock at a par value of $0.0001 per share, and is classified as an emerging growth company under SEC definitions. The 8-K was filed July 24, 2026, the day after the Nasdaq deficiency letter arrived.